March 3, 2020 10:56 AM EST
R&D

Boast­ing new dis­cov­er­ies from Xtan­di, Er­lea­da in­ven­tors, ORIC pitch­es $86M IPO on can­cer drugs tar­get­ed at re­sis­tance

Amber Tong

Months af­ter kick­ing off Phase Ib tri­als, a group of sea­soned can­cer drug de­vel­op­ers out of the Bay Area have filed for an $86 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

A service from the Financial Times